Melphalan may be a more potent leukemogen than cyclophosphamide

Annals of Internal Medicine

Volumn 105, Issue 3, 1986, Pages 360-367

  Greene, M H ^a   Harris, E L ^a   Gershenson, D M ^a   Malkasian Jr , G D ^b   Melton III, L J ^b   Dembo, A J ^b   Bennett, J M ^b   Moloney, W C ^b   Boice Jr , J D ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ALTRETAMINE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; FLUOROURACIL; MELPHALAN; THIOTEPA;

ACUTE NONLYMPHOCYTIC LEUKEMIA; ADVERSE DRUG REACTION; BLOOD AND HEMOPOIETIC SYSTEM; CANCER CHEMOTHERAPY; CANCER RISK; CHEMICAL CARCINOGENESIS; DRUG COMPARISON; DRUG THERAPY; ENDOCRINE SYSTEM; FEMALE GENITAL SYSTEM; HUMAN; IATROGENIC DISEASE; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; OVARY CANCER; PRELEUKEMIA; PREVENTION; PRIORITY JOURNAL; RADIOTHERAPY; SURVIVAL; THERAPY;

EID: 0022540018     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-105-3-360     Document Type: Article

References (0)